By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Neos Therapeutics 

2940 North Highway 360
Suite #400
Grand Prairie  Texas  75050  U.S.A.
Phone: 972-408-1300 Fax: 972-408-1143


SEARCH JOBS

Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. Contact: HR@NeosTX.com.


Key Statistics


Email: HR@neostx.com
Ownership: Public

Web Site: Neos Therapeutics
Employees:
Symbol: NEOS
 




Segment
Drug Delivery





Company News
Neos Therapeutics (NEOS) Receives U.S. FDA Approval Of Adzenys ER (Amphetamine) Extended-Release Oral Suspension For The Treatment Of ADHD In Patients 6 Years And Older 9/18/2017 10:51:57 AM
Neos Therapeutics (NEOS) Announces Launch Of Cotempla XR-ODT (Methylphenidate) Extended-Release Orally Disintegrating Tablets For The Treatment Of ADHD In Patients 6 To 17 Years Old 9/5/2017 10:40:09 AM
Neos Therapeutics (NEOS) To Participate In Three September Conferences 8/30/2017 8:32:04 AM
Revisiting Neos Therapeutics (NEOS) Before Key FDA Date 8/28/2017 8:58:52 AM
Neos Therapeutics (NEOS) Reports Second Quarter 2017 Financial Results 8/8/2017 8:35:33 AM
Neos Therapeutics (NEOS) To Host Second Quarter 2017 Financial Results Conference Call On August 8, 2017 8/2/2017 10:11:20 AM
Neos Therapeutics (NEOS) Announces Pricing Of Underwritten Public Offering Of $32.4 Million Of Common Stock 6/27/2017 8:37:04 AM
Neos Therapeutics (NEOS) Announces Pricing Of Underwritten Public Offering Of $32.4 Million Of Common Stock 6/27/2017 8:18:23 AM
Neos Therapeutics (NEOS) Announces FDA Approval Of Cotempla XR-ODT (Methylphenidate) Extended-Release Orally Disintegrating Tablets For The Treatment Of ADHD In Patients 6 To 17 Years Old 6/20/2017 7:39:22 AM
Neos Therapeutics (NEOS) To Present At The JMP Securities 2017 Life Sciences Conference 6/14/2017 12:47:31 PM
12345678
//-->